Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ARCHIVE
ARCHIVE
- SCRIP Tokyo Office Moves
January 22, 2001
- Daiichi Pure Chemicals Starts Contract SNP Analysis Services
January 22, 2001
- Merger with Mitsui Pharm Strengthens Schering Group's Product Line
January 22, 2001
- 15 Researchers Win AstraZeneca Asthma Research Award
January 22, 2001
- Cancer to Be Next 'Franchise' Area Following CNS, GI Fields: Mr Shinoda of Eisai
January 22, 2001
- New Kosei-Rodosho Inaugurated on Jan. 6
January 22, 2001
- Kyushu Univ. Opens Master's Course to Train Specialized Medical Professionals
January 22, 2001
- National Organization Proposed to Train CRCs: Kyoto Univ. Seminar
January 22, 2001
- Kosei-Rodosho Wants to Settle All Drug Price Issues in 2002 Reform
January 22, 2001
- Ain Pharmaciez to Become No. 1 Dispensing Pharmacy Operator: Report
January 22, 2001
- medical facilities & nursing care news on brief
January 15, 2001
- REGULATORY NEWS IN BRIEF -2-
January 15, 2001
- Cooperation with Companies Is Essential: RIKEN Researcher
January 15, 2001
- Sales of Takeda's Blopress Skyrocket: Top 100 Products Ranking
January 15, 2001
- Tissue Engineering Chair Donated by BCS at Tokai Univ.
January 15, 2001
- NHI Price System Reform Shelved in Japan: US ITC Report
January 15, 2001
- abbreviation
January 15, 2001
- Growth of Morphine Consumption Slows Down
January 15, 2001
- Welfide: Business Forecasts Affected by Transfer of Business, Shares
January 15, 2001
- REGULATORY NEWS IN BRIEF -1-
January 15, 2001
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…